- Home
- CABA vs UCL Comparison
CABA vs UCL Comparison
Compare CABA & UCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CABA
- UCL
- Stock Information
- Founded
- CABA 2017
- UCL 2014
- Country
- CABA United States
- UCL Hong Kong
- Employees
- CABA N/A
- UCL N/A
- Industry
- CABA Biotechnology: Biological Products (No Diagnostic Substances)
- UCL Telecommunications Equipment
- Sector
- CABA Health Care
- UCL Consumer Discretionary
- Exchange
- CABA Nasdaq
- UCL Nasdaq
- Market Cap
- CABA 132.6M
- UCL 144.5M
- IPO Year
- CABA 2019
- UCL 2020
- Fundamental
- Price
- CABA $1.49
- UCL $3.53
- Analyst Decision
- CABA Strong Buy
- UCL
- Analyst Count
- CABA 7
- UCL 0
- Target Price
- CABA $12.43
- UCL N/A
- AVG Volume (30 Days)
- CABA 1.3M
- UCL 215.7K
- Earning Date
- CABA 08-07-2025
- UCL 08-13-2025
- Dividend Yield
- CABA N/A
- UCL N/A
- EPS Growth
- CABA N/A
- UCL N/A
- EPS
- CABA N/A
- UCL 0.02
- Revenue
- CABA N/A
- UCL $89,277,000.00
- Revenue This Year
- CABA N/A
- UCL N/A
- Revenue Next Year
- CABA N/A
- UCL $20.86
- P/E Ratio
- CABA N/A
- UCL $143.38
- Revenue Growth
- CABA N/A
- UCL 3.72
- 52 Week Low
- CABA $0.99
- UCL $0.80
- 52 Week High
- CABA $5.83
- UCL $4.19
- Technical
- Relative Strength Index (RSI)
- CABA 42.02
- UCL 54.32
- Support Level
- CABA $1.40
- UCL $3.03
- Resistance Level
- CABA $1.56
- UCL $4.11
- Average True Range (ATR)
- CABA 0.12
- UCL 0.44
- MACD
- CABA -0.01
- UCL -0.07
- Stochastic Oscillator
- CABA 20.83
- UCL 37.27
About CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.
About UCL uCloudlink Group Inc.
Ucloudlink Group Inc is engaged in the provision of data connectivity services and sales of Wi-Fi terminals and data related products to enable personal and enterprise users to access mobile internet in more than 100 countries and areas. Leveraging its inventive cloud SIM technology and architecture, the company redefine the mobile data connectivity experience, allowing users to gain access to mobile data traffic allowance shared by network operators on its marketplace. It has aggregated mobile data traffic allowances from 391 MNOs in 163 countries and regions in its cloud SIM architecture. The company derives maximum revenue from Japan.